|By PR Newswire||
|March 4, 2013 02:01 AM EST||
CRAWLEY, UK, March 4, 2013 /PRNewswire/ --
Insulin degludec is indicated for the treatment of diabetes mellitus in adults.
Novo Nordisk UK has announced that insulin degludec (brand name Tresiba®), a new once-daily basal insulin for adult patients with type 1 and type 2 diabetes, is available in the UK as a new treatment option.
Insulin degludec effectively reduces blood glucose levels in patients with type 1 and 2 diabetes, while significantly reducing the risk of night-time hypoglycaemia, compared with the most commonly prescribed basal insulin in the UK:
- 25% reduction in night-time hypoglycaemia for patients with type 1 diabetes [4.41 vs 5.86 episodes per patient year of exposure (PYE); p=0.02]
- 36% reduction in night-time hypoglycaemia for insulin naïve patients with type 2 diabetes [0.25 vs 0.39 episodes per PYE; p<0.04]
- There was no significant difference in the rate of confirmed overall hypoglycaemic episodes for insulin degludec versus insulin glargine in patients with type 1 diabetes (42.54 vs 40.18 episodes per patient year of exposure p=0.48) or for insulin naïve patients with type 2 diabetes (1.52 vs 1.85 per patient year of exposure; p=0.11)
Insulin degludec is a once-daily basal insulin which can be administered at any time of the day, however preferably at the same time every day. It is the first insulin to offer people with diabetes the flexibility in the timing of insulin administration on occasions when administration at the same time of day is not possible. A minimum of eight hours between injections should always be ensured,.
"Many of my patients tell me when I see them in clinic that they have difficulty taking their insulin at exactly the same time each day. This is often for reasons which we can all sympathise with and understand. For example picking children up from school or working irregular shifts at work. It is thus very useful that there is now an insulin which, because of its longer duration of action, is able to offer patients a bit more flexibility in terms of timing of their dose without compromising either their glycaemic control or risk of hypoglycaemia", commented Professor Melanie J Davies, Professor of Diabetes Medicine, University of Leicester and Honorary Consultant, University Hospitals of Leicester.
Hypoglycaemic episodes are one of the most common side effects of insulin treatment, and although insulin degludec significantly reduces night-time hypoglycaemia, hypoglycaemia is still the most frequent side effect. However, of particular concern is the risk of night-time hypoglycaemia; often when the patient is sleeping and therefore less aware of the onset of symptoms.
While reduced risk of hypoglycaemia has obvious benefits for the person with diabetes, it is also important for society in general. The economic impact of hypoglycaemia in the UK is particularly significant. In 2010/11, the estimated UK cost for severe hypoglycaemia was £30.4 million and for moderate hypoglycaemia £41.8 million. Each severe hypoglycaemic episode involving hospitalisation, costs the NHS an estimated £2,153 per person,. Almost 50% of severe hypoglycaemic episodes occur at night and the most severe night-time episodes can be fatal if left untreated. Severe episodes are estimated to be responsible for 6% of deaths in people with diabetes under the age of 40,.
Insulin degludec is available in two FlexTouch® pens: FlexTouch® U100, which is suitable for doses from 1 to 80 units per injection and dials in one unit increments, and FlexTouch® U200, which allows up to 160 units of insulin in one injection and dials in two unit increments. The U200 is the first prefilled pen that allows patients who need more than 80 units of basal insulin each day to inject only once.
"Novo Nordisk has a long heritage in changing the diabetes landscape with 90 years of innovation and leadership in diabetes care. Our focus is in developing treatments that address key challenges faced by patients and clinicians," said Peter Meeus, UK/IRE Managing Director, Novo Nordisk.
- ENDS -
Notes to Editors
About Tresiba® (insulin degludec)
Insulin degludec is a new once-daily basal insulin for adults with diabetes, discovered and developed by Novo Nordisk. Insulin degludec reduces blood glucose levels with a lower risk of night-time hypoglycaemia compared to insulin glargine. Furthermore, insulin degludec provides a duration of action beyond 42 hours, allowing for flexibility in day-to-day dosing time when needed (minimum of 8 hours between injections). Insulin degludec is available in FlexTouch®, Novo Nordisk's latest prefilled insulin pen, and is offered in two concentrations enabling maximum doses of up to 80 and 160 units per single injection. Insulin degludec is also available in a cartridge (Tresiba® Penfill®), designed to be used with Novo Nordisk insulin delivery systems.
Insulin degludec was approved for use in type 1 and type 2 diabetes on 21 January 2013 by the European Commission.
Indication: Insulin degludec is indicated for the treatment of diabetes mellitus in adults.
Safety: The most frequent side effects are hypoglycaemia and injection site reactions. Hypoglycaemia is the most frequently reported adverse reaction during treatment (very common, ≥1/10). Injection site reactions are usually mild and transitory and normally disappear during continued use (common, ≥1/100 to <1/10). Insulin degludec has been studied in a clinical trial programme involving more than 7,000 people with diabetes.
See the Summary of Product Characteristics (SmPC) for further information.
Diabetes (or diabetes mellitus) is a serious and challenging health condition that develops when there is too much sugar in the blood due to the body being unable to produce or respond to the hormone, insulin, in the normal way. Every three minutes, one person in the UK is diagnosed with diabetes, and approximately 2.9 million people have already been diagnosed with diabetes in the UK. This figure is projected to rise to 5 million by 2025.
Hypoglycaemia is an episode of low blood sugar which may lead to accidents, injuries and even death in severe cases,. It is estimated that 6% of diabetes-related deaths are linked to severe hypoglycaemic episodes. Despite advances in insulin therapy, the risk of hypoglycaemia remains a serious problem. Severe hypoglycaemic episodes (where assistance from another person is required and may result in hospitalisation) can lead to seizures, coma and even death if left untreated. Even non-severe hypoglycaemic episodes have a large impact on daily life for many people with diabetes, including lost productivity at work. People with type 1 diabetes suffer, on average, over three episodes per month (42.9 episodes per year). People with type 2 diabetes suffer, on average, over one episode per month (16.4 episodes per year). These episodes cause many people with diabetes and their relatives to live with the fear of the next episode every day.
About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit novonordisk.co.uk.
® Tresiba®, FlexTouch®, Penfill® and the APIS bull are trademarks owned by Novo Nordisk A/S.
- Tresiba® summary of product characteristics 2013.
- Zinman B et al., Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long) Diabetes Care. 2012;35(12):2464-71.
- Heller S et al., Insulin degludec, an ultra-long acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3 randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379:1489-1497.
- Ratner RE et al., Prospectively planned meta-analysis comparing hypoglycemia rates of insulin degludec with those of insulin glargine. Diabetes, Obesity and Metabolism. 2013;15(2):175-184.
- Meneghini L et al., The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in people with type 2 diabetes. Diabetes Care. 2013 [epub ahead of print] dow: 10.2337/dc12-1668.
- Leiter LA et al., Assessment of the Impact of Fear of Hypoglycemic Episodes on Glycemic and Hypoglycemia Management. Can J Diabetes. 2005;29:186-92.
- Allen KV et al., BM. Nocturnal hypoglycemia: clinical manifestations and therapeutic strategies toward prevention. Endocr Pract. 2003;9(6):530-43.
- Hex N et al., Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29(7):855-62.
- ISD Scotland. Available at URL: http://www.isdscotland.org/Health-Topics/Finance/Publications/2011-11-29/Costs_R910_2011.xls Last accessed: February 2013.
- Department of Health. Payment by results tariffs. Available at URL: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_124356 Last accessed: February 2013.
- Sovik O et al., Dead-in-bed syndrome in young diabetic patients. Diabetes Care. 1999;22(S2):B40-2.
- Novo Nordisk data on file. DOF-IDeg-130712-005.
- NHS Choices. Diabetes introduction. Available at URL: http://www.nhs.uk/Conditions/Diabetes/Pages/Introduction.aspx Last accessed: February 2013.
- Diabetes UK. State of the Nation 2012. Available at URL: http://www.diabetes.org.uk/Documents/Reports/State-of-the-Nation-2012.pdf Last accessed: February 2013.
- Cefalu CA et al., Controlling hypoglycemia in type 2 diabetes: which agent for which patient? J Fam Pract. 2005;54:855-62.
- American Diabetes Association Working Group on Hypoglycemia. Defining and reporting hypoglycemia in diabetes. Diabetes Care. 2005;28:1245-9.
- Bonds DE et al., The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340:B4909.
- Briscoe VJ et al., Hypoglycemia in type 1 and type 2 diabetes: physiology, pathophysiology and management. Clin Diabetes. 2006;24:115-21.
- Brod M et al., The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 2011;14:665-71.
- Donnelly LA et al., Frequency and Predictors of Hypoglycaemia in Type 1 and Insulin-Treated Type 2 Diabetes: A Population-Based Study. Diabet Med. 2005;22:749-55.
The Internet of Things (IoT) is growing rapidly by extending current technologies, products and networks. By 2020, Cisco estimates there will be 50 billion connected devices. Gartner has forecast revenues of over $300 billion, just to IoT suppliers. Now is the time to figure out how you’ll make money – not just create innovative products. With hundreds of new products and companies jumping into the IoT fray every month, there’s no shortage of innovation. Despite this, McKinsey/VisionMobile data...
Nov. 29, 2015 02:00 PM EST Reads: 483
Culture is the most important ingredient of DevOps. The challenge for most organizations is defining and communicating a vision of beneficial DevOps culture for their organizations, and then facilitating the changes needed to achieve that. Often this comes down to an ability to provide true leadership. As a CIO, are your direct reports IT managers or are they IT leaders? The hard truth is that many IT managers have risen through the ranks based on their technical skills, not their leadership ab...
Nov. 29, 2015 01:00 PM EST Reads: 410
Just over a week ago I received a long and loud sustained applause for a presentation I delivered at this year’s Cloud Expo in Santa Clara. I was extremely pleased with the turnout and had some very good conversations with many of the attendees. Over the next few days I had many more meaningful conversations and was not only happy with the results but also learned a few new things. Here is everything I learned in those three days distilled into three short points.
Nov. 29, 2015 01:00 PM EST Reads: 348
DevOps is about increasing efficiency, but nothing is more inefficient than building the same application twice. However, this is a routine occurrence with enterprise applications that need both a rich desktop web interface and strong mobile support. With recent technological advances from Isomorphic Software and others, rich desktop and tuned mobile experiences can now be created with a single codebase – without compromising functionality, performance or usability. In his session at DevOps Su...
Nov. 29, 2015 12:45 PM EST Reads: 416
As organizations realize the scope of the Internet of Things, gaining key insights from Big Data, through the use of advanced analytics, becomes crucial. However, IoT also creates the need for petabyte scale storage of data from millions of devices. A new type of Storage is required which seamlessly integrates robust data analytics with massive scale. These storage systems will act as “smart systems” provide in-place analytics that speed discovery and enable businesses to quickly derive meaningf...
Nov. 29, 2015 12:30 PM EST Reads: 420
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
Nov. 29, 2015 12:00 PM EST Reads: 525
In his General Session at 17th Cloud Expo, Bruce Swann, Senior Product Marketing Manager for Adobe Campaign, explored the key ingredients of cross-channel marketing in a digital world. Learn how the Adobe Marketing Cloud can help marketers embrace opportunities for personalized, relevant and real-time customer engagement across offline (direct mail, point of sale, call center) and digital (email, website, SMS, mobile apps, social networks, connected objects).
Nov. 29, 2015 11:45 AM EST Reads: 324
The buzz continues for cloud, data analytics and the Internet of Things (IoT) and their collective impact across all industries. But a new conversation is emerging - how do companies use industry disruption and technology enablers to lead in markets undergoing change, uncertainty and ambiguity? Organizations of all sizes need to evolve and transform, often under massive pressure, as industry lines blur and merge and traditional business models are assaulted and turned upside down. In this new da...
Nov. 29, 2015 11:30 AM EST Reads: 272
In recent years, at least 40% of companies using cloud applications have experienced data loss. One of the best prevention against cloud data loss is backing up your cloud data. In his General Session at 17th Cloud Expo, Sam McIntyre, Partner Enablement Specialist at eFolder, presented how organizations can use eFolder Cloudfinder to automate backups of cloud application data. He also demonstrated how easy it is to search and restore cloud application data using Cloudfinder.
Nov. 29, 2015 10:00 AM EST Reads: 201
The Internet of Everything is re-shaping technology trends–moving away from “request/response” architecture to an “always-on” Streaming Web where data is in constant motion and secure, reliable communication is an absolute necessity. As more and more THINGS go online, the challenges that developers will need to address will only increase exponentially. In his session at @ThingsExpo, Todd Greene, Founder & CEO of PubNub, exploreed the current state of IoT connectivity and review key trends and t...
Nov. 29, 2015 09:45 AM EST Reads: 451
Two weeks ago (November 3-5), I attended the Cloud Expo Silicon Valley as a speaker, where I presented on the security and privacy due diligence requirements for cloud solutions. Cloud security is a topical issue for every CIO, CISO, and technology buyer. Decision-makers are always looking for insights on how to mitigate the security risks of implementing and using cloud solutions. Based on the presentation topics covered at the conference, as well as the general discussions heard between sessi...
Nov. 29, 2015 09:15 AM EST Reads: 344
We all know that data growth is exploding and storage budgets are shrinking. Instead of showing you charts on about how much data there is, in his General Session at 17th Cloud Expo, Scott Cleland, Senior Director of Product Marketing at HGST, showed how to capture all of your data in one place. After you have your data under control, you can then analyze it in one place, saving time and resources.
Nov. 29, 2015 08:45 AM EST Reads: 216
With all the incredible momentum behind the Internet of Things (IoT) industry, it is easy to forget that not a single CEO wakes up and wonders if “my IoT is broken.” What they wonder is if they are making the right decisions to do all they can to increase revenue, decrease costs, and improve customer experience – effectively the same challenges they have always had in growing their business. The exciting thing about the IoT industry is now these decisions can be better, faster, and smarter. Now ...
Nov. 29, 2015 08:00 AM EST Reads: 270
The cloud. Like a comic book superhero, there seems to be no problem it can’t fix or cost it can’t slash. Yet making the transition is not always easy and production environments are still largely on premise. Taking some practical and sensible steps to reduce risk can also help provide a basis for a successful cloud transition. A plethora of surveys from the likes of IDG and Gartner show that more than 70 percent of enterprises have deployed at least one or more cloud application or workload. Y...
Nov. 29, 2015 07:00 AM EST Reads: 499
Continuous processes around the development and deployment of applications are both impacted by -- and a benefit to -- the Internet of Things trend. To help better understand the relationship between DevOps and a plethora of new end-devices and data please welcome Gary Gruver, consultant, author and a former IT executive who has led many large-scale IT transformation projects, and John Jeremiah, Technology Evangelist at Hewlett Packard Enterprise (HPE), on Twitter at @j_jeremiah. The discussion...
Nov. 29, 2015 06:45 AM EST Reads: 742